Related Experiment Video
Updated: Aug 20, 2025

Cell-Free DNA Integrity Analysis in Urine Samples
Published on: January 5, 2017
Circulating Tumor Cells and Circulating Tumor DNA in Urologic Cancers
Ikenna Madueke1, Richard J Lee1, David T Miyamoto1
1Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.
Abstract:
Liquid biopsies such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have great potential to serve as prognostic and predictive biomarkers in urologic cancers. The possibility of using liquid biopsies for real-time noninvasive and dynamic monitoring of response to therapy has been an active area of investigation. In this brief review, we outline the evidence for the potential clinical utility of CTC and ctDNA analyses in prostate, urothelial, and renal cancers.

